Low molecular glycozaminoglycans prevention placental insufficiency in women with gestational hypertension

Aim. To improve the outcomes of pregnancy and childbirth, based on early diagnosis of endothelial dysfunction in women with hypertension without significant proteinuria and conducting medical and preventive actions aimed at its correction. Methods. Study design: a comparative longitudinal prospective cohort. We examined 80 women, ЗО of them - with gestational hypertension, received comprehensive treatment using sulodexide, 30 - the same without sulodexide and 20 - with normal blood pressure (control). Research methods included: clinical, laboratory (study of the hemostatic system, spontaneous and stimulated platelet aggregation, von Willebrand factor), functionality (ultrasonic and fetometry placentometry, Doppler, electrocardiography, kardiomonitoring of the fetus), and morphological methods (macroscopic and organometric of placenta). Results. The analysis of the effect of therapeutic factor (sulodexide) largest odds ratio in patients with gestational hypertension (GAG ) compared with conventional therapy showed that CRF OR=0,18 (95 % CI 0,18-0,54), VZRP OR=0,16 (95 % Cl 0,04-0,48 ), hypoxia OR=0,15 (95 % Cl 0,04-0,59). That is a retrospective comparison of the influence of this factor on the two groups showed a significant decrease these complications when using it. Conclusions. The effectiveness of complex treatment in the early stages of placental insufficiency in women with gag using LMWH is determined at a frequency of chronic placental failure (23,3 % vs. 63,3 %) and the risk of chronic fetal hypoxia and intrauterine growth retardation reduced by З times and depends on the severity of compensatory reactions of the placenta.

gestational hypertension, placental insufficiency, sulodexide